The Group’s history

Opocrin’s history started in 1964 with the insight of Pietro Bianchini and his passion for pharmacological studies and research.

An expert on mucopolysaccharides, he played an important role in the Italian and European scenarios, cooperating in the drafting of the Pharmacopoeia. His innovating spirit and dedication towards scientific research still inspire the Group’s companies to this day. Since 2008, Opocrin’s research and development laboratories have been dedicated to his memory.

TIMELINE

1964

Establishment of Opocrin S.p.A.

Since 1964, Opocrin S.p.A. has made researching, manufacturing and marketing active pharmaceutical ingredients derived from animal organs and tissues its core business.

1973

Opocrin S.p.A. concludes the first sales of Heparin Sodium

1975

Opocrin S.p.A. buys a new manufacturing site in Nonantola (Modena)

1976

Opocrin S.p.A. starts manufacturing new products of international interest

Manufacture of Catalase, Heparin Calcium, Sulodexide and Mesoglycan

1984

Development of a low-molecular-weight Heparin

Creation of a heparin known initially as OP21-23 and subsequently as Parnaparin (official INN).

1988

Study and manufacture of natural Surfactant for the treatment of RDS

Contracted by a leading international multinational to develop and manufacture natural Surfactant for the treatment of Neonatal Respiratory Distress Syndrome (RDS).

1994

Start of the manufacture of porcine pulmonary Surfactant in the dedicated new manufacturing site

1998

Opocrin S.p.A. obtains CE certification for its medical products containing collagen

1999

Opocrin S.p.A. becomes a supplier of active pharmaceutical ingredients of animal origin

Opocrin S.p.A. is classified by the FDA and by the Canadian authorities as an acceptable supplier for active pharmaceutical ingredients of animal origin.

2012

Study, development and creation of the production process for a polysaccharide of vegetable origin (Arabinogalactan)

2020

Opocrin S.p.A. acquires 100% of Laboratori Derivati Organici (LDO) shares and the Opocrin Group is born

2021

Opocrin S.p.A. acquires a majority stake in Omikron Italia s.r.l.

Omikron Italia is a Pharmaceutical Company intending to be a partner for Specialists and General Practitioners able to answer in an exhaustive and gradual way to the therapeutic needs of Vascular patients and of those affected by main eye diseases.